受注:045-509-1970 |
技術サポート:[email protected] 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
製品コード:A2002 Batch: A200209
Nivolumab is a genetically engineered, fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. MW : 143.597 KD.
CAS No. | 946414-94-4 |
---|---|
Formulation | PBS buffer, pH 7.2 |
Isotype | Human IgG4 |
Source | CHO cells |
Storage (From the date of receipt) |
Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles |
Shipping | Shipped under low temperature conditions |
Purity | 99% |
Protein concentration | 10.84mg/ml |
Endotoxin Level | <1EU/mg |
数据来源于[Data independently produced by , , Clin Cancer Res, 2019, doi:10.1158/1078-0432]
Apoptosis rates of Jurkat cells co-cultured for 72 h with H1975, A549 cells or H1975 with 10 μg/mL nivolumab were analyzed by Annexin V-FITC/PI assay (Left) and quantified (Right).
数据来源于[Data independently produced by , , Ann Surg Oncol, 2019, 26(1):139-147]
Preliminary immunotherapy drug screening using immune checkpoint inhibitors pembrolizumab and nivolumab in LGA organoids immune-enhanced with cells from a lymph node from the same patient. Mitochondrial metabolism was assessed at (c) 24 h and (d) 96 h after administration of the immunotherapy agents. Statistical significance: **p<0.05 between tumor cell-only and immune-enhanced organoids; p<0.05 between drug treatment and control of the same group.
Genomic and transcriptomic profiling of peripheral T cell lymphoma reveals distinct molecular and microenvironment subtypes [ Cell Rep Med, 2024, 5(2):101416] | PubMed: 38350451 |
NKG2A+CD8+ T cells infiltration determines immunosuppressive contexture and inferior response to immunotherapy in clear cell renal cell carcinoma [ J Immunother Cancer, 2024, 12(1)e008368] | PubMed: 38262706 |
[ Transl Oncol, 2024, ] | PubMed: 38412661 |
Tumor associated neutrophils governs tumor progression through an IL-10/STAT3/PD-L1 feedback signaling loop in lung cancer [ Transl Oncol, 2024, 40:101866] | PubMed: 38128466 |
Variable PD-1 glycosylation modulates the activity of immune checkpoint inhibitors [ Life Sci Alliance, 2024, 7(3)e202302368] | PubMed: 38176728 |
A murine model to evaluate immunotherapy effectiveness for human Fanconi anemia-mutated acute myeloid leukemia [ PLoS One, 2024, 19(1):e0292375] | PubMed: 38289944 |
Acquired resistance to CDK4/6 inhibition is associated with dysregulation of multiple pathways including cyclin D-CDK4/6-RB, EGFR/HER, AKT/mTOR and IFN [ Research Square, 2024, 10.21203/rs.3.rs-3782509/v1] | PubMed: none |
Base editing screens map mutations affecting interferon-γ signaling in cancer [ Cancer Cell, 2023, S1535-6108(22)00595-5] | PubMed: 36669486 |
Low-dose carboplatin modifies the tumor microenvironment to augment CAR T cell efficacy in human prostate cancer models [ Nat Commun, 2023, 14(1):5346] | PubMed: 37660083 |
Skin basal cell carcinomas assemble a pro-tumorigenic spatially organized and self-propagating Trem2+ myeloid niche [ Nat Commun, 2023, 14(1):2685] | PubMed: 37164949 |
人間や獣医の診断であるか治療的な使用のためにでない。